Research
Hormonal
Emerging agents now include multi-agonists, amylin-based therapies, novel oral compounds, and combination strategies designed to improve not only the magnitude of weight loss, but also its quality, durability, and metabolic consequences.
Practitioners should be aware of new multi-agonist and combination therapies that may offer enhanced benefits for weight loss and metabolic health.
StrongSupportsmedium confidence
Emerging agents now include multi-agonists, amylin-based therapies, novel oral compounds, and combination strategies designed to improve not only the magnitude of weight loss, but also its quality, durability, and metabolic consequences.
Why this rating
The claim is based on recent clinical evidence.
Source
Beyond <scp>GLP</scp> ‐1 Monotherapy: Novel Multi‐Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes
Mikhail Khachaturov et al. · Diabetes Obesity and Metabolism · 2026
review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →